The University of California, Los Angeles (UCLA) is launching a fundraising initiative to help improve treatment for advanced lung diseases, including sarcoidosis. The fundraising effort — called the Lung Health Research Accelerator Fund — aims to generate a total $20 million for the creation of a new research…
News
Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…
The soluble interleukin 2 receptor (sIL-2R) is more sensitive and specific than the angiotensin-converting enzyme (ACE), one of the most common diagnostic biomarkers of sarcoidosis, at identifying people who might have the disease, a study found. The findings were reported in the study, “Sensitivity and specificity of…
Transbronchial Lung Cryobiopsy Helps Provide Definitive Diagnose of Sarcoidosis, Study Suggests
Transbronchial lung cryobiopsy — a relatively new method of collecting lung tissue for analysis — safely and successfully helps to provide a definitive sarcoidosis diagnosis when the usual and less-invasive diagnostic tools are insufficient, a Portuguese study suggests. The study, “Diagnostic yield and safety of transbronchial…
Tears in blood vessels of the heart can occur in people with cardiac sarcoidosis, a case report found, although the incidence of this complication appears to be low. The report, “Spontaneous coronary artery dissection in cardiac sarcoidosis,” was published in Oxford Medical Case Reports. Spontaneous coronary…
Depression and anxiety may worsen the quality of life and lung function of patients with pulmonary sarcoidosis, a study has found. The findings of the study, “Psychological burden associated with worse clinical outcomes in sarcoidosis,” were published in the journal BMJ Open Respiratory Research. Statistics…
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Ofev (nintedanib) for the treatment of patients with sarcoidosis and other types of progressive fibrosing interstitial lung diseases (ILDs). The breakthrough designation is given to medications that provide significant advantages over…
Mycophenolate Mofetil May Be Effective as Alternative Sarcoidosis Treatment, Small Study Suggests
Mycophenolate mofetil (MMF) significantly reduced disease symptoms in people with sarcoidosis, and helped to reduce their daily dose of corticosteroids, a small study suggests. The study, “Mycophenolate mofetil as an alternative treatment in sarcoidosis,” was published in the…
LAS System May Fail to Identify Sarcoidosis Patients at Urgent Need of Lung Transplant, Study Finds
The current scoring system used to assess the urgency of lung transplants, called LAS (lung allocation score), fails to predict the risk of death in people with sarcoidosis, a single center study suggests. The study “Mortality for sarcoidosis patients on the transplant wait list in the…
Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board of directors. “The pace of discovery in rare diseases has gone from brisk to hypersonic,” Summar told Bionews Services, publisher…
Recent Posts
- We need to keep sharing our stories and reject the ‘sickfluencer’ narrative
- Cell-released proteins may predict sarcoidosis treatment response
- Registry study finds heart sarcoidosis outcomes vary by feature
- Critical conversations: Why talking about our medications is essential
- Study challenges theory of microbes as sarcoidosis cause
- FDA, developer align on protocols for trial of pulmonary sarcoidosis drug
- Large study ties sarcoidosis to risk of permanent liver scarring
- Reflecting with gratitude on what sarcoidosis has brought to my life
- Lingering heart inflammation tied to cardiac sarcoidosis relapse risk
- Study identifies three genes that may influence sarcoidosis risk